285. Fanconi anemia Clinical trials / Disease details
Clinical trials : 62 / Drugs : 93 - (DrugBank : 30) / Drug target genes : 30 - Drug target pathways : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04483544 (ClinicalTrials.gov) | December 3, 2020 | 20/7/2020 | Pembrolizumab and Olaparib in Cervical Cancer Patients | Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway | Cervical Cancer;Cervical Carcinoma | Drug: pembrolizumab;Drug: olaparib | Baptist Health South Florida | Florida Department of Health;Merck Sharp & Dohme LLC | Recruiting | 18 Years | N/A | Female | 48 | Phase 2 | United States |
| 2 | NCT04042831 (ClinicalTrials.gov) | June 9, 2020 | 29/7/2019 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | A Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | ARID1A Gene Mutation;ATM Gene Mutation;ATR Gene Mutation;Bile Duct Adenocarcinoma;BRCA1 Gene Mutation;BRCA2 Gene Mutation;BRIP1 Gene Mutation;CHEK2 Gene Mutation;EMSY Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;Metastatic Bile Duct Carcinoma;MRE11 Gene Mutation;NBN Gene Mutation;PALB2 Gene Mutation;PTEN Gene Deletion;RAD51 Gene Mutation | Drug: Olaparib | Academic and Community Cancer Research United | National Cancer Institute (NCI) | Recruiting | 18 Years | N/A | All | 36 | Phase 2 | United States |